• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

具有改善的溶出速率和增强的物理稳定性的拉西地平 - 螺内酯共无定形固体分散体系统。

Co-amorphous solid dispersion systems of lacidipine-spironolactone with improved dissolution rate and enhanced physical stability.

作者信息

Wang Zhaomeng, Sun Mengchi, Liu Tian, Gao Zisen, Ye Qing, Tan Xiao, Hou Yanxian, Sun Jin, Wang Dun, He Zhonggui

机构信息

Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.

Key Laboratory of Structure-Based Drug Design & Discovery of Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China.

出版信息

Asian J Pharm Sci. 2019 Jan;14(1):95-103. doi: 10.1016/j.ajps.2018.11.001. Epub 2018 Nov 14.

DOI:10.1016/j.ajps.2018.11.001
PMID:32104442
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7032115/
Abstract

Co-amorphous solid dispersion (C-ASD) systems have attracted great attention to improve the solubility of poorly soluble drugs, but the selection of an appropriate stabilizer to stabilize amorphous forms is still a huge challenge. Herein, C-ASD system of two clinical combined used drugs (lacidipine (LCDP) and spironolactone (SPL)) as stabilizers to each other, was prepared by solvent evaporation method. The effects of variation in molar ratio of LCDP and SPL (3:1, 1:1, 1:3, 1:6, and 1:9) on the drug release characteristics were explored. Polarized light microscopy (PLM), powder X-ray diffraction (PXRD), differential scanning calorimetry (DSC) and thermogravimetric analysis (TGA) were employed to evaluate the solid states. Prepared C-ASDs were further studied for their stability under the high humidity (RH 92.5%). Further analysis of C-ASDs via Fourier-transform infrared spectroscopy (FTIR) and Raman spectroscopy confirmed that hydrogen bond interactions between the two drugs played a significant role in maintaining the stability of the C-ASDs systems. Moreover, molecular dynamic (MD) simulations provided a clear insight into the stability mechanism at the molecular level. This study demonstrated the novel drug-drug C-ASDs systems is a promising formulation strategy for improved dissolution rate and enhanced physical stability of poorly soluble drugs.

摘要

共无定形固体分散体(C-ASD)系统在提高难溶性药物溶解度方面备受关注,但选择合适的稳定剂来稳定无定形形式仍然是一个巨大的挑战。在此,通过溶剂蒸发法制备了两种临床联合使用药物(拉西地平(LCDP)和螺内酯(SPL))相互作为稳定剂的C-ASD系统。探讨了LCDP与SPL摩尔比变化(3:1、1:1、1:3、1:6和1:9)对药物释放特性的影响。采用偏光显微镜(PLM)、粉末X射线衍射(PXRD)、差示扫描量热法(DSC)和热重分析(TGA)来评估固态。对制备的C-ASD在高湿度(RH 92.5%)下的稳定性进行了进一步研究。通过傅里叶变换红外光谱(FTIR)和拉曼光谱对C-ASD进行的进一步分析证实,两种药物之间的氢键相互作用在维持C-ASD系统的稳定性方面发挥了重要作用。此外,分子动力学(MD)模拟在分子水平上为稳定性机制提供了清晰的见解。本研究表明,新型药物-药物C-ASD系统是一种有前途的制剂策略,可提高难溶性药物的溶出速率并增强其物理稳定性。

相似文献

1
Co-amorphous solid dispersion systems of lacidipine-spironolactone with improved dissolution rate and enhanced physical stability.具有改善的溶出速率和增强的物理稳定性的拉西地平 - 螺内酯共无定形固体分散体系统。
Asian J Pharm Sci. 2019 Jan;14(1):95-103. doi: 10.1016/j.ajps.2018.11.001. Epub 2018 Nov 14.
2
Solid-state characterization of lacidipine/PVP K(29/32) solid dispersion primed by solvent co-evaporation.溶剂共蒸发引发的拉西地平/PVP K(29/32)固体分散体的固态表征
Int J Pharm Investig. 2012 Apr;2(2):90-6. doi: 10.4103/2230-973X.100048.
3
Lacidipine Amorphous Solid Dispersion Based on Hot Melt Extrusion: Good Miscibility, Enhanced Dissolution, and Favorable Stability.基于热熔挤出的拉西地平无定形固体分散体:良好的混溶性、增强的溶解性能和良好的稳定性。
AAPS PharmSciTech. 2018 Oct;19(7):3076-3084. doi: 10.1208/s12249-018-1134-9. Epub 2018 Aug 9.
4
Exploration of supersaturable lacidipine ternary amorphous solid dispersion for enhanced dissolution and in vivo absorption.探索拉西地平三元无定形固体分散体以提高溶解性能和体内吸收。
Eur J Pharm Sci. 2019 Nov 1;139:105043. doi: 10.1016/j.ejps.2019.105043. Epub 2019 Aug 12.
5
A Comparison of Spray-Drying and Co-Precipitation for the Generation of Amorphous Solid Dispersions (ASDs) of Hydrochlorothiazide and Simvastatin.喷雾干燥法和共沉淀法制备氢氯噻嗪和辛伐他汀无定形固体分散体的比较。
J Pharm Sci. 2023 Aug;112(8):2097-2114. doi: 10.1016/j.xphs.2023.02.012. Epub 2023 Feb 18.
6
Solvent-shift strategy to identify suitable polymers to inhibit humidity-induced solid-state crystallization of lacidipine amorphous solid dispersions.用于鉴定合适聚合物以抑制拉西地平无定形固体分散体湿度诱导的固态结晶的溶剂转移策略。
Int J Pharm. 2016 Apr 30;503(1-2):238-46. doi: 10.1016/j.ijpharm.2016.01.062. Epub 2016 Feb 8.
7
Amorphous solid dispersion of nisoldipine by solvent evaporation technique: preparation, characterization, in vitro, in vivo evaluation, and scale up feasibility study.溶剂蒸发技术制备硝苯地平无定形固体分散体:制备、表征、体外、体内评价及放大可行性研究。
Drug Deliv Transl Res. 2020 Aug;10(4):903-918. doi: 10.1007/s13346-020-00775-8.
8
Role of polymers in the physical and chemical stability of amorphous solid dispersion: A case study of carbamazepine.聚合物在无定形固体分散体物理和化学稳定性中的作用:以卡马西平为例。
Eur J Pharm Sci. 2022 Feb 1;169:106086. doi: 10.1016/j.ejps.2021.106086. Epub 2021 Nov 30.
9
Soluplus-Mediated Diosgenin Amorphous Solid Dispersion with High Solubility and High Stability: Development, Characterization and Oral Bioavailability.聚乙二醇聚乙烯己内酰胺介导的具有高溶解度和高稳定性的薯蓣皂苷元无定形固体分散体:研发、表征及口服生物利用度
Drug Des Devel Ther. 2020 Jul 27;14:2959-2975. doi: 10.2147/DDDT.S253405. eCollection 2020.
10
Reactive Melt Extrusion To Improve the Dissolution Performance and Physical Stability of Naproxen Amorphous Solid Dispersions.反应性熔融挤出法改善萘普生无定形固体分散体的溶出性能和物理稳定性
Mol Pharm. 2017 Mar 6;14(3):658-673. doi: 10.1021/acs.molpharmaceut.6b00960. Epub 2017 Feb 10.

引用本文的文献

1
Amorphous Solid Dispersions of Glycyrrhetinic Acid: Using Soluplus, PVP, and PVPVA as the Polymer Matrix to Enhance Solubility, Bioavailability, and Stability.甘草次酸的无定形固体分散体:使用聚乙烯己内酰胺-聚乙酸乙烯酯-聚乙二醇接枝共聚物(Soluplus)、聚乙烯吡咯烷酮(PVP)和聚乙烯吡咯烷酮-醋酸乙烯酯共聚物(PVPVA)作为聚合物基质来提高溶解度、生物利用度和稳定性。
AAPS PharmSciTech. 2024 Dec 21;26(1):18. doi: 10.1208/s12249-024-03007-1.
2
Formulating abiraterone acetate-HPMCAS-based amorphous solid dispersions: insights into and biorelevant dissolution assessments and pharmacokinetic evaluations.基于醋酸阿比特龙-羟丙基甲基纤维素醋酸琥珀酸酯的无定形固体分散体的制备:深入了解及与生物相关的溶出度评估和药代动力学评价
RSC Adv. 2024 Dec 5;14(52):38492-38505. doi: 10.1039/d4ra08163c. eCollection 2024 Dec 3.
3

本文引用的文献

1
Virtual population pharmacokinetic using physiologically based pharmacokinetic model for evaluating bioequivalence of oral lacidipine formulations in dogs.使用基于生理的药代动力学模型进行虚拟群体药代动力学研究,以评估犬口服拉西地平制剂的生物等效性。
Asian J Pharm Sci. 2017 Jan;12(1):98-104. doi: 10.1016/j.ajps.2016.03.003. Epub 2016 Mar 21.
2
Enhanced oral absorption of pemetrexed by ion-pairing complex formation with deoxycholic acid derivative and multiple nanoemulsion formulations: preparation, characterization, and in vivo oral bioavailability and anticancer effect.利用与去氧胆酸衍生物形成离子对复合物和多种纳米乳剂制剂增强培美曲塞的口服吸收:制备、表征、体内口服生物利用度和抗癌作用。
Int J Nanomedicine. 2018 Jun 6;13:3329-3351. doi: 10.2147/IJN.S167958. eCollection 2018.
3
Preparation and Characterization of Lutein Co-Amorphous Formulation with Enhanced Solubility and Dissolution.具有增强溶解度和溶出度的叶黄素共无定形制剂的制备与表征
Foods. 2024 Jun 26;13(13):2029. doi: 10.3390/foods13132029.
4
Influence of Intermolecular Interactions on Crystallite Size in Crystalline Solid Dispersions.分子间相互作用对结晶性固体分散体中微晶尺寸的影响
Pharmaceutics. 2023 Oct 19;15(10):2493. doi: 10.3390/pharmaceutics15102493.
5
A Comparative Assessment of Cocrystal and Amorphous Solid Dispersion Printlets Developed by Hot Melt Extrusion Paired Fused Deposition Modeling for Dissolution Enhancement and Stability of Ibuprofen.热熔挤出-熔融沉积成型制备共晶和无定形固体分散体打印片剂提高布洛芬溶出度和稳定性的比较评估
AAPS PharmSciTech. 2023 Oct 2;24(7):203. doi: 10.1208/s12249-023-02666-w.
6
Continuous Manufacturing and Molecular Modeling of Pharmaceutical Amorphous Solid Dispersions.连续制造和药物无定形固体分散体的分子建模。
AAPS PharmSciTech. 2022 Sep 2;23(7):249. doi: 10.1208/s12249-022-02408-4.
7
Deaggregation and Crystallization Inhibition by Small Amount of Polymer Addition for a Co-Amorphous Curcumin-Magnolol System.少量聚合物添加对姜黄素-厚朴酚共无定形体系的解聚和结晶抑制作用
Pharmaceutics. 2021 Oct 18;13(10):1725. doi: 10.3390/pharmaceutics13101725.
8
Pulmonary Drug Delivery of Antimicrobials and Anticancer Drugs Using Solid Dispersions.使用固体分散体进行抗菌药物和抗癌药物的肺部给药
Pharmaceutics. 2021 Jul 10;13(7):1056. doi: 10.3390/pharmaceutics13071056.
Physical Stability and Dissolution Behavior of Ketoconazole-Organic Acid Coamorphous Systems.酮康唑-有机酸共无定形系统的物理稳定性和溶解行为。
Mol Pharm. 2018 May 7;15(5):1862-1869. doi: 10.1021/acs.molpharmaceut.8b00035. Epub 2018 Apr 9.
4
Moisture-Induced Amorphous Phase Separation of Amorphous Solid Dispersions: Molecular Mechanism, Microstructure, and Its Impact on Dissolution Performance.无定形固体分散体的水分诱导无定形相分离:分子机制、微观结构及其对溶解性能的影响。
J Pharm Sci. 2018 Jan;107(1):317-326. doi: 10.1016/j.xphs.2017.10.028. Epub 2017 Oct 26.
5
Probing Pharmaceutical Mixtures during Milling: The Potency of Low-Frequency Raman Spectroscopy in Identifying Disorder.研磨过程中药物混合物的探测:低频 Raman 光谱在识别无序态方面的作用。
Mol Pharm. 2017 Dec 4;14(12):4675-4684. doi: 10.1021/acs.molpharmaceut.7b00803. Epub 2017 Nov 16.
6
Coamorphous Active Pharmaceutical Ingredient-Small Molecule Mixtures: Considerations in the Choice of Coformers for Enhancing Dissolution and Oral Bioavailability.共无定形活性药物成分-小分子混合物:增强溶解和口服生物利用度的共晶选择考虑因素。
J Pharm Sci. 2018 Jan;107(1):5-17. doi: 10.1016/j.xphs.2017.09.024. Epub 2017 Oct 5.
7
Facile formation of co-amorphous atenolol and hydrochlorothiazide mixtures via cryogenic-milling: Enhanced physical stability, dissolution and pharmacokinetic profile.低温研磨法制备阿替洛尔-氢氯噻嗪共无定形混合物:增强物理稳定性、溶出度和药代动力学特征。
Int J Pharm. 2017 Oct 30;532(1):393-400. doi: 10.1016/j.ijpharm.2017.09.020. Epub 2017 Sep 8.
8
Supersaturating drug delivery systems: The potential of co-amorphous drug formulations.超饱和药物递送系统:共无定形药物制剂的潜力。
Int J Pharm. 2017 Oct 30;532(1):1-12. doi: 10.1016/j.ijpharm.2017.08.123. Epub 2017 Sep 1.
9
Viewing Molecular and Interface Interactions of Curcumin Amorphous Solid Dispersions for Comprehending Dissolution Mechanisms.通过观察姜黄素无定形固体分散体的分子和界面相互作用来理解溶解机制。
Mol Pharm. 2017 Aug 7;14(8):2781-2792. doi: 10.1021/acs.molpharmaceut.7b00319. Epub 2017 Jul 7.
10
Mechanism-based selection of stabilization strategy for amorphous formulations: Insights into crystallization pathways.基于机制的无定形制剂稳定化策略选择:对结晶途径的见解
J Control Release. 2017 Jun 28;256:193-202. doi: 10.1016/j.jconrel.2017.04.015. Epub 2017 Apr 12.